The analyzer performs PD-L1 TPS classification that enhances objective and accurate analysis compared with traditional methods, the company said. The product was trained with more than 1 million cancer cell images to analyze PD-L1 biomarker expression and classifies PD-L1 TPS into three groups: 50% or more, 1% to 49%, and 0%.
This digitized assistance substantially supports pathologists in diagnosing the status with high accuracy and consistency, the company said in a release. Lunit is working on launching Lunit SCOPE PD-L1 in Europe in the second half of 2022.
Copyright © 2022 AuntMinnieEurope.com